"We are honored and proud to welcome Dr. Gormley to the executive management team at Gemin X. His strategic leadership background, clinical development experience and understanding of the pharmaceutical industry is a perfect match for Gemin X as we advance our novel cancer programs into late-stage clinical development and look towards partnerships and commercialization,” stated Robert G. McNeil, Ph.D., Chairman of Gemin X’s Board of Directors.
“Gemin X’s cancer programs are promising because the drug candidates in development, including obatoclax in Phase 2 clinical trials and GMX1777 in a Phase 1 trial, target highly specialized cancer pathways that are key to the growth and progression of cancer. Equally strong candidates are under development preclinically. The Company’s strong oncology pipeline therefore has the potential to make an important impact on the lives of cancer patients. I am honored to have the opportunity to join such a prestigious scientific and business leadership team,” said Dr. Gormley.
Dr. Gormley most recently was Global Head of Clinical Development and Medical Affairs at Novartis. Prior to Novartis, he was Chief Medical Officer at AstraZeneca and a member of the executive management team. While at AstraZeneca Dr. Gormley served as a member of the Board of Trustees at the University of Delaware. Before joining AstraZeneca, he was Vice President and Head of U.S. Clinical Development at Merck & Co.
Dr. Gormley received his M.D. and Ph.D. in Chemistry from the University of Chicago and received board certifications in Pediatrics from UCLA and in Endocrinology from New York University.
About Gemin X Pharmaceuticals
Gemin X Pharmaceuticals specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT), resulting in cancer cell death independently of the tumor suppressor p53. It is currently in a Phase 1 clinical trial in patients with refractory solid tumors and lymphomas. Gemin X is privately held and is located in Malvern, Pennsylvania and Montreal, Canada. www.geminx.com Contacts
MacDougall Biomedical Communications Douglas MacDougall, 781-235-3060 or Gemin X Pharmaceuticals Diane Viens, 514-281-8989 x387 ir@geminx.com
